LEXARIA BIOSCIENCE CORP. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
LEXARIA BIOSCIENCE CORP. (LEXX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $3.41 per share for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-11-30 was $3.41, a 36.73% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-11-30 was $5.39, a 1153.49% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-11-30 was $0.43.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-02-29 was $0.47.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $1.11.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $4.09, a 2626.67% increase from fiscal 2019.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2019 was $0.15, a 11.76% decline from fiscal 2018.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2018 was $0.17, a 0.00% change from fiscal 2017.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-05-31 | $3.41 10-Q · filed 2026-07-13 | |||||
| 2026-02-28 | $3.44 10-Q · filed 2026-04-13 | |||||
| 2025-11-30 | $3.41 10-Q · filed 2026-01-13 | |||||
| 2025-05-31 | $5.90 10-Q · filed 2025-07-14 | |||||
| 2025-02-28 | $5.39 10-Q · filed 2025-04-14 | |||||
| 2024-11-30 | $5.39 10-Q · filed 2025-01-10 | |||||
| 2024-08-31 | $1.11 10-K · filed 2025-11-28 | |||||
| 2024-05-31 | $1.11 10-Q · filed 2024-07-12 | |||||
| 2024-02-29 | $0.54 10-Q · filed 2024-04-09 | |||||
| 2023-11-30 | $0.43 10-Q · filed 2024-01-12 | |||||
| 2021-05-31 | $0.00 10-Q · filed 2021-07-15 | |||||
| 2020-08-31 | $4.09 10-K · filed 2021-11-29 | $0.14 10-K · filed 2020-10-15 | ||||
| 2020-05-31 | $0.10 10-Q · filed 2020-06-29 | |||||
| 2020-02-29 | $0.47 10-Q · filed 2020-04-03 | $0.10 10-Q · filed 2020-04-03 | ||||
| 2019-11-30 | $4.09 10-Q · filed 2021-01-14 | $0.55 10-Q · filed 2020-01-09 | ||||
| 2019-08-31 | $0.15 10-K · filed 2020-10-15 | |||||
| 2019-05-31 | $1.08 10-Q · filed 2019-07-08 | |||||
| 2019-02-28 | $0.14 10-Q · filed 2019-04-15 | |||||
| 2018-11-30 | $0.10 10-Q · filed 2019-01-11 | |||||
| 2018-08-31 | $0.17 10-K · filed 2019-11-14 | |||||
| 2018-05-31 | $0.24 10-Q · filed 2018-07-13 | |||||
| 2018-02-28 | $0.19 10-Q · filed 2018-04-12 | |||||
| 2017-11-30 | $0.23 10-Q · filed 2018-01-12 | |||||
| 2017-08-31 | $0.17 10-K · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |